Inmune Bio, Inc.
A clinical-stage biotech reprogramming the immune system to fight cancer and neurodegeneration.
INMB | US
Overview
Corporate Details
- ISIN(s):
- US45782T1051
- LEI:
- Country:
- United States of America
- Address:
- 225 NE MIZNER BLVD, SUITE 640, 33432 BOCA RATON
- Website:
- https://www.inmunebio.com/
- Sector:
- Manufacturing
Description
Inmune Bio, Inc. is a clinical-stage biotechnology company that develops therapies by reprogramming the patient's innate immune system to fight disease. The company's pipeline is focused on treating cancer and neurodegenerative disorders, particularly Alzheimer's disease. Its lead product candidates include XPro1595, a selective inhibitor of soluble Tumor Necrosis Factor (TNF) for treating neuroinflammation, and INKmune®, a tumor-agnostic therapy designed to prime a patient's natural killer (NK) cells to attack cancer. Inmune Bio's clinical development approach prioritizes matching a drug's mechanism of action to patient biology and using patient-centric outcome metrics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Inmune Bio, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Inmune Bio, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Inmune Bio, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
